Kyowa Kirin discontinues ongoing trials of rocatinlimab

​Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation for moderate-to-severe AD, prurigo nodularis, and moderate-to-severe asthma.

The post Kyowa Kirin discontinues ongoing trials of rocatinlimab appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Droplet improves genomic analysis speed using NVIDIA Parabricks software
Esperion to acquire Corstasis for cardiovascular franchise expansion
Roche’s Phase III trial of fenebrutinib in RMS meets primary endpoint
PHCbi unveils cell expansion system for research use 
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us